Fleming T R
Biometrics. 1982 Mar;38(1):143-51.
Commonly, the central objective of Phase II clinical trials is the assessment of the antitumor 'therapeutic efficacy' of a specific treatment regimen. It is of interest to formulate test procedures which can be employed in these trials to decide whether or not this therapeutic efficacy warrants further investigation. For ethical reasons, these procedures should allow for early termination if initial results are extreme. In this paper, a one-sample multiple testing procedure is proposed which employs the standard single-stage test procedure at the last test, and which both allows for early termination and essentially preserves the size, power and simplicity of the single-stage procedure.
通常,II期临床试验的核心目标是评估特定治疗方案的抗肿瘤“治疗效果”。制定可用于这些试验的测试程序以确定这种治疗效果是否值得进一步研究是很有意义的。出于伦理原因,如果初始结果极差,这些程序应允许提前终止。本文提出了一种单样本多重测试程序,该程序在最后一次测试时采用标准单阶段测试程序,既允许提前终止,又基本保持了单阶段程序的规模、功效和简单性。